Innovative clinical study: a successful step in COPD research
February 22, 2018
Great success in COPD research: An innovative clinical study performed by Fraunhofer ITEM has shown the drug under investigation to improve not only lung function in COPD patients, but to have a significantly positive effect on their heart function as well. The study investigated a combination drug from Novartis Pharma AG (indacaterol/glycopyrronium) that has already been approved for COPD treatment. The results were published in the renowned journal "The Lancet Respiratory Medicine".
Phase-I drug interaction study in Crohn’s disease patients initiated
February 2, 2018
In close collaboration with the Clinic for Gastroenterology, Hepatology and Endocrinology at the Hannover Medical School, the potential of ustekinumab to interfere with the pharmacokinetics of midazolam, warfarin, omeprazole, dextromethorphan, and caffeine is being explored at the CRC Hannover in a phase-I study with patients with moderate to severe Crohn's disease.
New sleep laboratory: first study with a new antidepressant drug
January 25, 2018
Fraunhofer ITEM has extended the diagnostic possibilities in its clinical research by setting up a sleep laboratory with 4 beds in the phase-I unit of the Clinical Research Center Hannover.
FUNCTIONAL MRI STUDY CONFIRMED RELIABILITY OF ARTERIAL SPIN LABELING
November 24, 2017
In a clinical study for method validation, performed in close collaboration with the Institute for Radiology of the Hannover Medical School, scientists were able to demonstrate that functional MRI with arterial spin labeling is a reliable method for quantification of kidney perfusion.
Observational study in cases of COPD
July 21, 2017
The lung disease, COPD, usually caused by smoking, is associated with chronic coughing and shortness of breath. It has a detrimental effect on quality of life and in its advanced stages, it is a frequent cause of death. Apart from pulmonary function tests, there have been no suitable biomarkers (biological parameters, for example certain blood-based messengers) in the bodies of those affected hitherto which indicate the severity or predict the progression of the disease. In a major international study, which the Fraunhofer ITEM is participating in, COPD patients having various degrees of severity and healthy ex-smokers are to be observed over a period of two years.